GS vs. PFE
GS (The Goldman Sachs Group, Inc.) and PFE (Pfizer Inc.) are both stocks. GS operates in Capital Markets (Financial Services), while PFE operates in Drug Manufacturers - General (Healthcare). Over the past 10 years, GS returned 23.45%/yr vs 2.09%/yr for PFE. At a 0.31 correlation, their price movements are largely independent.
Performance
GS vs. PFE - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, GS achieves a 19.31% return, which is significantly higher than PFE's 8.09% return. Over the past 10 years, GS has outperformed PFE with an annualized return of 23.45%, while PFE has yielded a comparatively lower 2.09% annualized return.
GS
- 1D
- -4.94%
- 1M
- 11.30%
- YTD
- 19.31%
- 6M
- 22.72%
- 1Y
- 74.88%
- 3Y*
- 50.51%
- 5Y*
- 24.53%
- 10Y*
- 23.45%
PFE
- 1D
- 1.36%
- 1M
- -0.23%
- YTD
- 8.09%
- 6M
- 3.39%
- 1Y
- 20.50%
- 3Y*
- -6.48%
- 5Y*
- -2.98%
- 10Y*
- 2.09%
GS vs. PFE - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
GS The Goldman Sachs Group, Inc. | 19.31% | 56.64% | 52.03% | 15.91% | -7.87% | 47.61% | 17.45% | 40.48% | -33.53% | 7.73% |
PFE Pfizer Inc. | 8.09% | 0.65% | -2.22% | -41.26% | -10.41% | 66.70% | 3.07% | -6.91% | 24.82% | 15.90% |
Correlation
The correlation between GS and PFE is 0.17, which is low. Their price movements are largely independent, making them effective diversification partners.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.17 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.24 |
Correlation (5Y) Calculated over the trailing 5-year period | 0.23 |
Correlation (10Y) Calculated over the trailing 10-year period | 0.26 |
Correlation (All Time) Calculated using the full available price history since May 5, 1999 | 0.31 |
The correlation between GS and PFE shifts across timeframes, from 0.17 (1 year) to 0.31 (all time), reflecting how their relationship changes across market environments.
Fundamentals
GS:
$319.91B
PFE:
$149.24B
GS:
$57.41
PFE:
$1.31
GS:
18.09
PFE:
19.85
GS:
2.34
PFE:
0.36
GS:
2.95
PFE:
2.35
GS:
2.60
PFE:
1.66
GS:
$110.77B
PFE:
$63.32B
GS:
$61.53B
PFE:
$43.91B
GS:
$24.94B
PFE:
$16.94B
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
GS vs. PFE — Risk / Return Rank
GS
PFE
GS vs. PFE - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for The Goldman Sachs Group, Inc. (GS) and Pfizer Inc. (PFE). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
| GS | PFE | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | +1.82 | ||
| Sortino ratioReturn per unit of downside risk | +1.85 | ||
| Omega ratioGain probability vs. loss probability | 1.43 | 1.17 | +0.26 |
| Calmar ratioReturn relative to maximum drawdown | 3.88 | 1.79 | +2.08 |
| Martin ratioReturn relative to average drawdown | 12.98 | 3.68 | +9.30 |
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month. | |||
Loading charts...
Sharpe Ratios by Period
| GS | PFE | Difference | |
|---|---|---|---|
Sharpe Ratio (1Y)Calculated over the trailing 1-year period | 2.68 | 0.86 | +1.82 |
Sharpe Ratio (5Y)Calculated over the trailing 5-year period | 0.88 | -0.12 | +1.00 |
Sharpe Ratio (10Y)Calculated over the trailing 10-year period | 0.79 | 0.09 | +0.70 |
Sharpe Ratio (All Time)Calculated using the full available price history | 0.33 | 0.33 | 0.00 |
Drawdowns
GS vs. PFE - Drawdown Comparison
The maximum GS drawdown since its inception was -78.84%, which is greater than PFE's maximum drawdown of -69.24%. Use the drawdown chart below to compare losses from any high point for GS and PFE.
Loading charts...
Drawdown Indicators
| GS | PFE | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -78.84% | -69.24% | -9.60% |
Max Drawdown (1Y)Largest decline over 1 year | -19.42% | -11.47% | -7.95% |
Max Drawdown (3Y)Largest decline over 3 years | -30.90% | -40.75% | +9.85% |
Max Drawdown (5Y)Largest decline over 5 years | -32.84% | -58.96% | +26.12% |
Max Drawdown (10Y)Largest decline over 10 years | -48.75% | -58.96% | +10.21% |
Current DrawdownCurrent decline from peak | -4.94% | -46.03% | +41.09% |
Average DrawdownAverage peak-to-trough decline | -22.62% | -22.89% | +0.27% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 5.79% | 5.59% | +0.20% |
Volatility
GS vs. PFE - Volatility Comparison
The Goldman Sachs Group, Inc. (GS) has a higher volatility of 10.72% compared to Pfizer Inc. (PFE) at 4.50%. This indicates that GS's price experiences larger fluctuations and is considered to be riskier than PFE based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| GS | PFE | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 10.72% | 4.50% | +6.22% |
Volatility (6M)Calculated over the trailing 6-month period | 23.01% | 14.66% | +8.35% |
Volatility (1Y)Calculated over the trailing 1-year period | 28.11% | 23.92% | +4.19% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 28.03% | 25.50% | +2.53% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 29.83% | 23.88% | +5.95% |
Dividends
GS vs. PFE - Dividend Comparison
GS's dividend yield for the trailing twelve months is around 1.64%, less than PFE's 6.61% yield.
| Position | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
GS The Goldman Sachs Group, Inc. | 1.64% | 1.59% | 2.01% | 2.72% | 2.62% | 1.70% | 1.90% | 1.80% | 1.89% | 1.14% | 1.09% | 1.41% |
PFE Pfizer Inc. | 6.61% | 6.91% | 6.33% | 5.70% | 3.12% | 2.64% | 3.92% | 3.68% | 3.12% | 3.53% | 3.69% | 3.47% |
Financials
GS vs. PFE - Financials Comparison
This section allows you to compare key financial metrics between The Goldman Sachs Group, Inc. and Pfizer Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
GS vs. PFE - Profitability Comparison
GS - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, The Goldman Sachs Group, Inc. reported a gross profit of 16.91B and revenue of 17.23B. Therefore, the gross margin over that period was 98.2%.
PFE - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Pfizer Inc. reported a gross profit of 9.72B and revenue of 14.45B. Therefore, the gross margin over that period was 67.3%.
GS - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, The Goldman Sachs Group, Inc. reported an operating income of 6.49B and revenue of 17.23B, resulting in an operating margin of 37.7%.
PFE - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Pfizer Inc. reported an operating income of 4.03B and revenue of 14.45B, resulting in an operating margin of 27.9%.
GS - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, The Goldman Sachs Group, Inc. reported a net income of 5.63B and revenue of 17.23B, resulting in a net margin of 32.7%.
PFE - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Pfizer Inc. reported a net income of 2.69B and revenue of 14.45B, resulting in a net margin of 18.6%.
Frequently Asked Questions
GS and PFE have a correlation of 0.17, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
GS has higher volatility (10.72%) compared to PFE (4.50%). In terms of maximum drawdown, GS dropped -78.84% vs PFE's -69.24%.
GS currently has the higher Sharpe Ratio (2.68 vs 0.86), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for GS and PFE
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer